miR‐221 and Parkinson's disease: A biomarker with therapeutic potential
European Journal of Neuroscience · 2024
DOI: 10.1111/ejn.16207 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Neuroscience, 2024. Verfasst von Mohammad Yasin Zamanian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. Hauptthemen laut MEDLINE: Parkinson Disease, MicroRNAs. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 156 Literaturangaben.
Abstract (Originalsprache)
Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, leading to various motor and non‐motor symptoms. Several cellular and molecular mechanisms such as alpha‐synuclein (α‐syn) accumulation, mitochondrial dysfunction, oxidative stress and neuroinflammation are involved in the pathogenesis of this disease. MicroRNAs (miRNAs) play important roles in post‐transcriptional gene regulation. They are typically about 21–25 nucleotides in length and are involved in the regulation of gene expression by binding to the messenger RNA (mRNA) molecules. miRNAs like miR‐221 play important roles in various biological processes, including development, cell proliferation, differentiation and apoptosis. miR‐221 promotes neuronal survival against oxidative stress and neurite outgrowth and neuronal differentiation. Additionally, the role of miR‐221 in PD has been investigated in several studies. According to the results of these studies, (1) miR‐221 protects PC12 cells against oxidative stress induced by 6‐hydroxydopamine; (2) miR‐221 prevents Bax/caspase‐3 signalling activation by stopping Bim; (3) miR‐221 has moderate predictive power for PD; (4) miR‐221 directly targets PTEN, and PTEN over‐expression eliminates the protective action of miR‐221 on p‐AKT expression in PC12 cells; and (5) miRNA‐221 controls cell viability and apoptosis by manipulating the Akt signalling pathway in PD. This review study suggested that miR‐221 has the potential to be used as a clinical biomarker for PD diagnosis and stage assignment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
- Department of Physiology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.
- School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.
- Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.
- Symbiosis Institute of Business Management (SIBM), Hyderabad, India.
- Symbiosis International (Deemed University) (SIU), Hyderabad, Telangana, India.
Zitieren
APA
Zamanian, M. Y., Ivraghi, M. S., Gupta, R., Prasad, K. D. V., Alsaab, H. O., Hussien, B. M., Ahmed, H., Ramadan, M. F., Golmohammadi, M., Nikbakht, N., Oz, T., & Kujawska, M. (2024). miR‐221 and Parkinson's disease: A biomarker with therapeutic potential. European Journal of Neuroscience. https://doi.org/10.1111/ejn.16207
Vancouver
Zamanian MY, Ivraghi MS, Gupta R, Prasad KDV, Alsaab HO, Hussien BM, et al. miR‐221 and Parkinson's disease: A biomarker with therapeutic potential. European Journal of Neuroscience. 2024. doi:10.1111/ejn.16207
BibTeX
@article{Zamanian2024,
author = {Zamanian, Mohammad Yasin and Ivraghi, Mehraveh Sadeghi and Gupta, Reena and Prasad, K D V and Alsaab, Hashem O and Hussien, Beneen M and Ahmed, Hazem and Ramadan, Montather F and Golmohammadi, Maryam and Nikbakht, Nikta and Oz, Tuba and Kujawska, Małgorzata},
title = {miR‐221 and Parkinson's disease: A biomarker with therapeutic potential},
journal = {European Journal of Neuroscience},
year = {2024},
doi = {10.1111/ejn.16207}
}
EUVIMED